CTMX(CytomX Therapeutics, Inc.) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。
| 科目 | FY 截至 2021-12-31 | FY 截至 2022-12-31 | FY 截至 2023-12-31 | FY 截至 2024-12-31 | FY 截至 2025-12-31 |
|---|---|---|---|---|---|
| 营业收入 | $37.31M | $53.16M | $101.21M | $138.10M | $76.20M |
| 毛利润 | — | — | — | — | — |
| 营业利润 | −$116.04M | −$101.33M | −$6.48M | $25.00M | −$22.36M |
| 净利润 | −$115.87M | −$99.32M | −$569.00K | $31.87M | −$17.37M |
| 经营现金流 | −$119.03M | −$110.79M | −$56.03M | −$86.23M | −$75.59M |
| 自由现金流 | −$120.64M | −$112.53M | −$56.88M | −$86.54M | −$75.81M |
| 摊薄每股收益 | — | — | — | — | — |